Nestel PJ, and Fidge NH: The physiology of plasma lipoproteins. In: Lipoproteins, Atherosclerosis and Coronary Heart Disease, ed. by Miller NE and Lewis B.Amsterdam, Elsevier/North Holland Biomedical Press , 1981, p. 3.
2.
Brown MS, Kovanen PT and Goldstein JL: Regulation of plasma cholesterol by lipoprotein receptors. Science212:628, 1981.
3.
Altschul R., Hoffer A. and Stephen JD: Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys54:558, 1955.
4.
Krishna G., Weiss B., Davies JI, et al: Mechanism of nicotinic acid inhibition of hormone-induced lipolysis . Fed Proc25:719, 1966.
5.
Nikkila EA: Effects of nicotinic acid on adipose tissue lipoprotein lipase and removal rate of plasma triglycerides. In: Metabolic Effects of Nicotinic Acid and Its Derivatives, ed. by Gey KF and Carlson LA.Bern, Hans Huber, 1971, p. 487.
6.
Nunn SL, Tauxe WN and Juergens JL: Effect of nicotinic acid in human cholesterol biosynthesis. Circ24:1099, 1981.
7.
Hunninghake DB, and Probstfield JL: Drug treatment of hyperlipidemia. In: Hyperlipidemia: Diagnosis and Therapy, ed. by Rifkind BM and Levy RI.New York, Grune and Stratton, 1977, p. 327.
8.
Carlson LA, Ekelund LG and Oro L.: Clinical and metabolic effects of different doses of prostaglandin E 1 in man: Prostaglandin and related factors. Acta Med Scand183:423, 1968.
9.
Carlson LA, Walldius G. and Butcher RW: Effect of chlorophenoxyisobutyric acid (CPIB) on rate-mobilizing lipolysis and cyclic AMP levels in rat epididymal fat pads. Atherosclerosis16:349, 1972.
10.
Maragandakis ME, and Hankin H.: On the mode of action of lipid lowering agents. V. Kinetics of the inhibition in vitro of rat acetyl coA carbosylase. J Biochem246:348, 1971.
11.
Tarentino AL , Richert DA and Westerfield WW: The concurrent induction of hepatic -glycerophosphate dehydrogenase and ma-late dehydrogenase by thyroid hormone. Biochem Biophys Acta124:295, 1966.
12.
Gould RG, Swyryd EA, Avoy D., et al: The effects of -p-chlorophenoxyisobutyrate on the synthesis and release into plasma of lipoproteins in rats. Prog Biochem Pharmacol2:345, 1957.
13.
Thompson GR: Dietary and pharmacological control of lipoprotein metabolism. In: Lipoproteins, Atherosclerosis and Coronary Heart Disease, ed. by Miller NE and Lewis B.Amsterdam, Elsiever/North Holland Biomed Press, 1981, p. 129.
14.
Wilson DE, and Lees RS: Metabolic relationships among the plasma lipoproteins. J Clin Invent51:1051, 1972.
15.
Report from the Committee of Principal Investigators: A cooperative trial in the primary prevention of ischemic heart disease using clofibrate . Br Heart J40:1069, 1978.
16.
Hulley SB, Rosenbaum RH, Bawol RD, et al: Epidemiology as a guide to clinical decisions: the associations between triglyceride and coronary heart disease. NEJM302:1383, 1980.
17.
The Coronary Drug Project Research Group : Clofibrate and niacin in coronary heart disease. JAMA231:360, 1975.
18.
Langer T., and Levy RI: Acute muscular syndrome associated with administration of clofibrate. NEJM229:856, 1968.
19.
Miettinen TA : Mode of action of a new hypocholesterolemic drug (DH-581) in familial hypercholesterolemia. Atherosclerosis15:163, 1972.
20.
Barnhart JW , Sefranka JA and McIntosh DD: Hypocholesterolemic effect of 4,4'-(isopropylidenedithio) bis (2,6-di-t-butylphenol) (probucol). Amer J Clin Nutr23:1229, 1970.
21.
LeLorier J. , DuBreuil-Quidoz S., Lussier-Cacan S., et al: Diet and probucol in lowering cholesterol concentrations. Arch Intern Med137:1429, 1977 .
22.
Enjalbert M. , Lussier-Cacan S., Dubeuil-Quidoz S., et al: Usefulness of probucol in treating hypercholesterolemia. Can Med J123:754, 1980.
23.
Hunninghake DB, Bell D. and Olson L.: Effect of probucol in plasma lipids and lipoproteins in Type IIb hyperlipoproteinemia. Ather37:469, 1980.
24.
Gagne C., Lupien PJ, Brun D., Moorjani S., et al: Probucol and high-density-lipoprotein cholesterol. Can Med J123:356, 1980.
25.
Slater HR, Packard CJ, Bicker S., et al: Effects of cholestyramine on receptor-medicated plasma clearance and tissue uptake of human low-density lipoproteins in the rabbit. J Bio Chem255:10210, 1980.
26.
Shephard J. , Packard CJ, Bicker S., et al: Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. NEJM302:1219, 1980 .
27.
Levy RI(moderator), Discussants: Dietary and drug treatment of primary hyperlipoproteinemia, NIH conference. Ann Intern Med77:267, 1972.
28.
Khachadurion A.K: Cholestyramine therapy in patients homozygous for familial hypercholesterolemia. J Ather Res8:177, 1968.
29.
Clifton-Bligh P., Miller NE and Nestel PJ: Changes in plasma lipoprotein lipids in hypercholesterolemic patients treated with the bile-sequestering resin, colestipol. Clin Sci Mol Med47:547, 1974.
30.
Hunninghake DB, Probstfield JL, Crow LO, et al: Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia. Metabolism30:605, 1981.
31.
Hunninghake DB, Bell C. and Olson L.: Effect of colestipol and clofibrate, singly and in combinations, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia . Metabolism30:610, 1981.
32.
Boyden TW, and Totman L.: Synergistic effects of probucol and cholestyramine to lower serum cholesterol. JClin Pharm21:48, 1981.
33.
Kane JP, Malloy MJ, Tun P., et al: Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. NEJM304:251, 1981.
34.
Illingworth DR , Rapp JH, Phillipson BE, et al: Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolemia. LancetII:296, 1981.
35.
Mabuchi H., Haba T., Tatami R., et al: Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiguinine-10 levels in patients with familial hypercholesterolemia. NEJM305:478, 1981.
36.
Kissenbah AH , Adams PA and Wynn V.: Lipokinetic studies with gemfibrozil (CI-719) . Proc R Soc Med (Suppl)2:94, 1976.
37.
Kaukola S., Manninen V., Malkonen M., et al: Gemfibrozil in the treatment of dyslipidemias in middle-aged male survivors of myocardial infarction. Acta Med Scand209:69, 1981.
